RAPP (Rapport Therapeutics) Debt-to-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics Debt-to-Asset?

Rapport Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.74 Mil. Rapport Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.74 Mil. Rapport Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $314.93 Mil. Rapport Therapeutics's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Rapport Therapeutics Debt-to-Asset Historical Data

The historical data trend for Rapport Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics Debt-to-Asset Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Debt-to-Asset

0.01

Rapport Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial				0.01	0.01	0.01	0.01	0.01

Competitive Comparison of Rapport Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Rapport Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapport Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Rapport Therapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Rapport Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Rapport Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.737	+	0.739)	/	314.933
	=	0.00

Rapport Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.737	+	0.739)	/	314.933
	=	0.00

Rapport Therapeutics (NAS:RAPP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Rapport Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Rapport Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.